Metabolic syndrome; frequency and its relationship with variable parameters in chronic obstructive pulmonary disease
Azza Farag Said El-toneya, Bahaa Ibrahim Mohameda, Emad Allam Abd-Elnaemb, Alaa Shaban Ismaila

Background Chronic obstructive pulmonary disease (COPD) has many extrapulmonary comorbidities, and metabolic syndrome (MetS) is one of them. Scant data are available on MetS in Egyptian patients with COPD.

Objective The purpose of the current research was to determine the frequency and clinical characteristics of MetS among Egyptian patients with stable COPD.

Patients and methods A prospective study including 70 (64 males and six females) patients with stable COPD was conducted. Clinical assessment, pulmonary function, and other laboratory studies were performed.

Results MetS was present in 31 patients with COPD (44.3%). BMI and high-sensitivity C-reactive protein were significantly higher in patients with COPD with MetS than those without MetS ($P=0.02$ and 0.01, respectively). Age of the patients, duration of COPD, grade of dyspnea, and pulmonary function tests had no significant difference between those with MetS versus those without it. There was a significant negative correlation between plasma triglyceride level, as the only one of the variables of MetS, and some of parameters of pulmonary function test.

Conclusion MetS is relatively frequent among patients with COPD. Plasma triglyceride level is the only parameter of MetS to have a significant correlation with pulmonary function tests. Apart from BMI and high-sensitivity C-reactive protein, no other parameter among patients with COPD has a significant relationship with MetS.

Keywords: chronic obstructive pulmonary disease, high-sensitivity C-reactive protein, metabolic syndrome, pulmonary function tests

© 2019 Egyptian Journal of Bronchology

Egyptian Journal of Bronchology 2019 13:148–154

Introduction Metabolic syndrome (MetS) is a state of chronic low-grade inflammation as a consequence of a complex interplay between genetic and environmental factors. Insulin resistance, visceral adiposity, atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, elevated blood pressure, hypercoagulable state, and chronic stress are the several factors that constitute the syndrome [1].

In 2002, the National Cholesterol Education Progress devised a definition for the MetS [2]. According to this definition, MetS is present if there are three or more of the following five criteria: waist circumference exceeding more than or equal to 102 cm for men and at least 88 cm for women, fasting triglycerides (TGs) of at least 150 mg/dl, high-density lipoprotein-cholesterol (HDL-c) less than 40 mg/dl for men and less than 50 mg/dl for women, blood pressure at least 130/85 mmHg, and fasting plasma glucose of at least 110 mg/dl.

Chronic obstructive pulmonary disease (COPD) is accompanied by chronic inflammation of the airways and lung parenchyma [3].

Systemic inflammation is responsible for most of extrapulmonary manifestations of COPD. Spirometry is not the only method to determine the clinical severity of COPD, as it the clinical severity can also be detected by concomitant comorbidities. These comorbidities include affection of cardiovascular system, bronchogenic carcinoma, osteoporosis, weight loss, MetS, myopathy, and depression [4].

Although the pathobiology of COPD has not been well explained, systemic inflammation has been involved in the mechanism of most of its systemic effects [5], to the point that some authors have suggested that COPD is a part of a chronic systemic inflammation [6].

Approximately half of the patients with COPD had one or more criteria of the MetS [7]. Many reports have been published on the prevalence of the MetS in the Middle East among the general population, but limited one on its prevalence among patients with COPD, especially in our locality.

In this work, we aimed to assess the frequency of MetS in patients with stable COPD, and the relationships of
MetS with some clinical, inflammatory, and spirometric indices of COPD were also evaluated.

Materials and methods

Study population

This prospective study was done on 70 (64 males and six females) patients with stable COPD attending chest clinic of Cardiothoracic Minia University Hospital from October 2015 up to October 2016. This study was approved by the Ethical Committee of Faculty of Medicine, Minia University, and an informed consent was obtained from all participants.

Diagnosis of COPD was based on GOLD definition in the form of presence of risk factors like smoking, biomass fuel exposure, and occupational exposure in addition to presence of chronic cough and/or expectoration and dyspnea, with post-bronchodilator forced expiratory volume in first (FEV₁)/forced vital capacity (FVC) less than 0.7 (GOLD guidelines) [8].

Stable COPD was defined by the lack of hospitalization, urgent care visits, antibiotic use, or changes in medications within 4 weeks before the study.

Patients with an acute exacerbation of COPD within 1 month of the study as well as patients with a history of collagen vascular diseases and inflammatory bowel disease were excluded.

Clinical assessment

Patient demographics were recorded, including age, sex, smoking status, and duration of illness. Grading of dyspnea was done using modified Medical Research Council scale.

Clinical parameters like BMI were calculated [9]. Blood pressure and waist circumference were also measured. Waist circumference was measured using an inelastic tape [10].

Pulmonary function tests

Spirometry was done using 2130 spirometer (V max; Sensormedics, USA). Results were obtained for FVC, FEV₁, FEV₁/FVC percentage, forced expiratory flow at 25–75% of FVC, and peak expiratory flow rate. All parameters were calculated as percentages of predicted values.

Patients who had FEV₁/FVC less than 70% underwent post-bronchodilator spirometry, 20 min following two puffs of salbutamol 200 μg.

Laboratory assessment

Fasting blood glucose (FBG) and lipid profile in the form of plasma TGs and HDL-c after 12 h fasting using automated chemistry analyzer were measured.

Measurement of high-sensitivity C-reactive protein (hs-CRP) was also done; 3 ml venous blood samples were collected and centrifuged within 2 h of sampling. The serum was separated and was frozen and stored at −20°C until analyzed for measurement of hs-CRP by enzyme immunoassay kits supplied by European Authorized Representative (Immunospec Corporation).

Assay of high-sensitivity C-reactive protein by enzyme immunoassay

The assay system uses a unique monoclonal antibody directed against a distinct antigenic determinant on the hs-CRP molecule.

A goat anti-C-reactive protein (CRP) antibody is the antibody-enzyme (horseradish peroxidase) conjugate solution. The test sample is allowed to react simultaneously with the two antibodies, resulting in the CRP molecules being sandwiched between the solid phase and enzyme-linked antibodies. After 45-min incubation at room temperature, the wells are washed with water to remove unbound labeled antibodies.

A tetramethylbenzidine reagent is added and incubated for 20 min, resulting in the development of blue color. The color development is stopped with the addition of stop solution, and the color is changed to yellow. The concentration of hs-CPR is directly proportional to the color intensity of the test sample, which is read a microtiter well reader within 15 min.

Statistical analysis

Data entry and analysis were done using SPSS, version 19. The Student’s t-test was employed for comparative analysis of the quantitative variables. For the qualitative variables, either χ²-test or Fisher’s exact test was used. Correlation test (Pearson’s test) was used. The probability of less than 0.05 (P<0.05) * was used as a cutoff point for all significant values.

Results

Patient characteristics

Demographics and clinical features of patients with COPD are presented in Table 1. Based on NECT ATP III definition of MetS [2], we found that 31 (44.3%) patients with COPD had MetS, whereas 39 (55.7%) patients were without MetS. It was found that
BMI in patients with COPD with MetS was significantly higher than in patients with COPD without MetS (30.6 vs. 27.8, \( P = 0.02 \), respectively).

In addition, hs-CRP was also higher in patients with MetS than those without, with no significant difference in other parameters.

**Measurements and laboratory assessments**

There is a higher significant value of diastolic blood pressure in patients with COPD with MetS than those without MetS (80 vs. 74.3, \( P = 0.02 \), respectively). In addition, hs-CRP was also higher in patients with MetS than those without, with no significant difference in other parameters.

**Discussion**

A relation between MetS and COPD has been observed in some studies, and the syndrome has been identified as an independent risk factor for worsening respiratory symptoms, increasing lung function impairment, and pulmonary hypertension [11]. From this important point of view, this work was designed to detect first, the frequency of MetS in

---

**Table 1** Comparison of clinical characteristics of patients with chronic obstructive pulmonary disease with and without metabolic syndrome

| Data                        | Patients with COPD with MetS (N=31) | Patients with COPD without MetS (N=39) | \( P \)     |
|-----------------------------|-------------------------------------|----------------------------------------|-------------|
| Age (mean±SD)               | 59.0±6.5                            | 62.4±7.9                               | 0.06        |
| Sex                         |                                     |                                        |             |
| Male                        | 27 (87.1)                           | 37 (94.9)                              | 0.2         |
| Female                      | 4 (12.9)                            | 2 (5.1)                                |             |
| Duration of illness (years) | 12.4±7.2                            | 11.6±6.8                               | 0.9         |
| Current smoker              |                                     |                                        |             |
| Smoking                     | 6 (19.4)                            | 13 (33.3)                              | 0.4         |
| Ex-smoker                   | 19 (61.3)                           | 19 (48.7)                              |             |
| Nonsmoker                   | 6 (19.4)                            | 7 (17.9)                               |             |
| Pack/year                   | 20.7±5.7                            | 24.5±10.9                              | 0.1         |
| BMI                         | 30.6±5.1                            | 27.8±4.9                               | 0.02*       |
| GOLD stage                  |                                     |                                        |             |
| 1                           | 4 (12.9)                            | 5 (12.8)                               | 0.2         |
| 2                           | 13 (41.9)                           | 12 (30.7)                              |             |
| 3                           | 12 (38.7)                           | 12 (30.7)                              |             |
| 4                           | 2 (6.5)                             | 10 (25.6)                              | 0.4         |
| mMRC                        | 2.15±0.71                           | 1.5±0.62                               | 0.0         |
| hs-CRP (mg/l)               | 210.4±45.6                          | 130.2±30.5                             | 0.01*       |

Data are presented as n (%), mean±SD. COPD, chronic obstructive pulmonary disease; hs-CRP, high-sensitivity C-reactive protein; MetS, metabolic syndrome; mMRC, modified Medical Research Council. *\( p < 0.05 \) which means significant value.

---

**Table 2** Comparison of metabolic syndrome criteria among patients with chronic obstructive pulmonary disease with and without metabolic syndrome

| Data                     | COPD patients with metabolic syndrome (N=31) | COPD patients without metabolic syndrome (N=39) | \( P \)     |
|--------------------------|---------------------------------------------|-----------------------------------------------|-------------|
| WC                       | 107.4±6.8                                  | 104.7±7.1                                    | 0.1         |
| SBP                      | 121.2±8.4                                  | 120.2±8.4                                    | 0.6         |
| DBP                      | 80±7.3                                     | 74.3±12.5                                    | 0.03*       |
| TG                       | 168.1±77.1                                 | 124.4±66.6                                   | 0.01*       |
| HDL-c                    | 51.2±28.8                                  | 75.5±36.1                                    | 0.003*      |
| FBG                      | 205.1±110.2                                | 132.6±88.8                                   | 0.003*      |

Data are represented as mean±SD. COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-c, high-density lipoprotein-cholesterol; SBP, systolic blood pressure; TG, triglycerides; WC, waist circumference. *\( p < 0.05 \) which means significant value.

We found that 18 (25.6%) patients with COPD had one criterion of MetS; 21 (30%) patients had two criteria of MetS; 28 (40%) patients of COPD had three criteria of MetS, which were increased waist circumference, elevated TG level, and increased FBG; and three (4.4%) patients had four criteria of MetS (Fig. 1).

No significant difference was found regarding all parameters of spirometry between patients having COPD with and without MetS (Table 3).

**Correlation of spirometry and metabolic parameters**

Plasma TG as one of the components of MetS presented a significant negative correlations with both of FEV1 and FVC\% predicted (Figs 2 and 3, respectively) whereas there was no significant correlation between other parameters of spirometry and MetS criteria (Table 4).
patients with COPD, and we found that 44.3% of patients with COPD had MetS based on NECT ATP III definition [2]. In the literature, reports of prevalence of MetS in patients with COPD have rates ranging from 23 to 61% [7,12,13]. These considerable variations in frequency found in studies on MetS can be explained by different geographical origins of the study and the use of different diagnostic criteria for defining MetS. In addition, this prevalence of MetS did not determine if patients with COPD were studied in periods of acute exacerbations or in stable state.

COPD often results in a sedentary lifestyle and physical deconditioning, which could explain the presence of MetS in patients with COPD [7]. When components of MetS were evaluated one by one, we found that abdominal obesity was present in 78.6% of patients with COPD, elevated FBG in 65.7%, low HDL-C levels in 34.3%, elevated TG in 31.4%, and raised blood pressure in 2.9% (data not shown). So, abdominal obesity had the highest frequency as one criterion of MetS in patients with COPD. However, in the study by Ghatas [14], abdominal obesity, hypertension, and hyperglycemia were more prevalent in patients with COPD in descending order. The second commonest parameter of MetS in patients with COPD included in our study was FBG more than 110 mg/dl, which was present in 46 (65.7%) patients. Of 46 patients, 13 (28.2%) had impaired fasting glucose (IFG) which is defined as a FBG that is higher than the upper limit of normal, but not high enough to be classified as diabetes mellitus. We used WHO criteria of definition of IFG which means fasting plasma glucose level from 110 to 125 mg/dl [15]. The remaining 33 (71.8%) of 46 patients with COPD had diabetes mellitus, as their FBG levels were more than 126 mg/dl, 22 (66.6%) of them among those with MetS.

Impaired fasting glucose is one form of prediabetes; many newly identified IFG patients progress to diabetes in less than 3 years [15].

The second objective of this study was to determine the relationship of MetS with clinical, inflammatory and
pulmonary function parameters in patients with COPD.

On analysis of the baseline data of patients with COPD with MetS versus those without MetS, we found that there was no significant difference regarding age between patients with COPD with and without MetS (59.03 vs. 62.4, \( P=0.06 \)). This agrees with the results of Díez-Manglano et al. [16]. We found also that sex, duration of COPD, dyspnea grade, and
GOLD stage had no significant difference in those with or without MetS.

In the current study, BMI was significantly higher in patients with COPD with MetS versus those without (30.6 vs. 27.8, \( P = 0.02 \)), and this coincides with the results of Breyer et al. [17].

Patients with COPD experience a systemic inflammation even in stable state which can be assessed by measuring inflammatory mediators like CRP [18]. Serum hs-CRP was significantly higher in patients with COPD with MetS versus those without MetS (210.4±45.6 vs. 130.2±30.5, \( P = 0.01 \)). Our results were in accordance with previous studies [18–20]. However, Hotamisligil [21] concluded that it is not clear yet whether systemic inflammation associated with COPD causes metabolic disorders or metabolic signals trigger inflammatory response. We did not find a significant difference in all parameters of pulmonary function test among patients with COPD with and without MetS; on the contrary, Stanciu et al. [19] noted that patients with COPD with MetS show a significance difference than patients with COPD without MetS according to FEV1 and the 6-min walk test. Alpaydın et al. [22] found that FEV1 and FEV1/FVC were higher in patients with COPD with MetS compared with those without MetS. No obvious explanation was found for these discrepancies.

Regarding correlation of pulmonary function parameters and MetS criteria in patients with COPD (Table 4), we found a significant inverse correlation of TG only with FVC% and FEV1% \((r=-0.55, \ P=0.001\) and \( r=-0.61, \ P=0.001\), respectively). Ameen et al. [23] showed significant inverse (negative) relation between severity of COPD (FEV1) and all parameters of MetS except HDL which showed linear (positive) relation with FEV1. Popović-Grlje et al. [24] found that FVC and FEV1 correlated negatively with waist circumference; however, the correlation was weak and statistically nonsignificant, and this is in line with our results of FEV1 and FVC correlations with waist circumference.

The present study has some limitation; one of them is the small sample size of studied patients. Second, we have no data on the rate of exacerbation of patients with MetS versus those without MetS. Lastly, no follow-up information on the prognosis of patients with COPD with MetS is provided regarding the changes of lung function, impaired health-related quality of life, and increase mortality.

**Conclusion**

We found that 44% of patients with COPD have MetS, so MetS in our locality is frequent. With the exception of BMI and serum level of hs–CRP, no other clinical indicator for the presence of MetS is found. Increased serum level of TGs, as one of the components of MetS, is associated with more impairment in FEV1 and FVC. Abdominal obesity, impaired glucose level, and diabetes mellitus are the most frequent components of MetS found in patients with COPD.

So, an effort to throw light on MetS in patients with COPD should be undertaken in our locality. In addition, we recommend that preventive approaches to patients with COPD should be taken in the form of weight reduction and diet control with exercise; these lifestyle modifications can reduce the more frequent components that lead to the development of MetS.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**References**
1. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *EndocrinoMetab Clin North Am* 2004; 33:351–375.
2 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. Circulation 2002; 106:3143–3421.

3 Rabe KF, Hurst S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532–555.

4 Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28:1245–1257.

5 Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc 2007; 4:522–525.

6 Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370:797–799.

7 Marquis K, Maltais F, Duguay V, Bezeau AM, LeBlanc P, Jobin J, et al. Metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25:226–232.

8 Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2016); Global strategy for the diagnosis, management, and prevention of COPD. Available at: http://www.goldcopd.org. [Accessed date 2016]

9 Harik-khan RI, Fleg JI, Wise RA. Body mass index & risk of COPD. Chest 2002; 121:370–376.

10 WHO. WHO STEP wise approach to surveillance (STEPS). Geneva: World Health Organization (WHO); 2008.

11 Baffi CW, Wood L, Winnica D, Strollo PJ, Gladwin MT, Que LG, et al. Metabolic syndrome and the lung. Chest 2016; 149:1525–1534.

12 Funakoshi Y, Omori H, Mihara S, Katoh T. Association between airflow obstruction and the metabolic syndrome and its components in Japanese men. Intern Med 2010; 49:2093–2099.

13 Acharya A, Shahjahan MD, Mesbah FB, Dey SK, Ali L. Association of metabolic syndrome with chronic obstructive pulmonary disease in an Indian population. Lung India 2016; 33:385–390.

14 Ghatas T. The relationship between metabolic syndrome and chronic obstructive pulmonary disease. Egypt J Bronchol 2017; 11:11–15.

15 World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization 1999.

16 Diez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, López García F, Montero L, et al. Working Group on COPD, Spanish Society of Internal Medicine. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 2014; 9:419–425.

17 Breyer MK, Spruit MA, Hansson CK, Franssen FM, Vanfleteren LE, Groenen MT, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One 2014; 9:e98013.

18 Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250–255.

19 Stanciu S, Marinescu R, Iordache M, Dumitrescu S, Mureșan M, Bogdan MA. Are systemic inflammatory profiles different in patients with COPD and metabolic syndrome as compared to those with COPD alone? Rom J Intern Med 2009; 47:381–386.

20 Akpınar EE, Akpınar S, Ertel S, Sayın E, Gülhan M. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks 2012; 60:230–237.

21 Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860–867.

22 Alpaydìn AO, Arslan IK, Serter S, Coskun AS, Celik P, Tanlı F, Yorgancıoğlu A. Metabolic syndrome and carotid intima-media thickness in chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8:61.

23 Ameen NM, Mohamed RS, Abd El Mageed NI. The metabolic syndrome in patients with chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc 2016; 65:593–596.

24 Popović-Grle S, Ladić A, Butorac-Petanjek B, Špiček-Macan J, Ćutćević B. Waist circumference does not correlate with functional lung capacity in moderate and severe chronic obstructive pulmonary disease. Acta Clin Croat 2013; 52:69–77.